155 related articles for article (PubMed ID: 12750027)
41. Blockade by 1,3-dipropyl-8-cyclopentylxanthine (CPX) of purine protection against kainate neurotoxicity.
Macgregor DG; Stone TW
Brain Res; 1994 May; 644(2):339-42. PubMed ID: 8050046
[TBL] [Abstract][Full Text] [Related]
42. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.
Hauber W; Neuscheler P; Nagel J; Müller CE
Eur J Neurosci; 2001 Oct; 14(8):1287-93. PubMed ID: 11703457
[TBL] [Abstract][Full Text] [Related]
43. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists.
Sauer R; Maurinsh J; Reith U; Fülle F; Klotz KN; Müller CE
J Med Chem; 2000 Feb; 43(3):440-8. PubMed ID: 10669571
[TBL] [Abstract][Full Text] [Related]
44. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
45. Medicinal chemistry of A2A adenosine receptor antagonists.
Cacciari B; Pastorin G; Spalluto G
Curr Top Med Chem; 2003; 3(4):403-11. PubMed ID: 12570758
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.
Müller CE; Geis U; Hipp J; Schobert U; Frobenius W; Pawłowski M; Suzuki F; Sandoval-Ramírez J
J Med Chem; 1997 Dec; 40(26):4396-405. PubMed ID: 9435909
[TBL] [Abstract][Full Text] [Related]
47. Medicinal chemistry and pharmacology of A2B adenosine receptors.
Volpini R; Costanzi S; Vittori S; Cristalli G; Klotz KN
Curr Top Med Chem; 2003; 3(4):427-43. PubMed ID: 12570760
[TBL] [Abstract][Full Text] [Related]
48. Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors.
Szymańska E; Drabczyńska A; Karcz T; Müller CE; Köse M; Karolak-Wojciechowska J; Fruziński A; Schabikowski J; Doroz-Płonka A; Handzlik J; Kieć-Kononowicz K
Bioorg Med Chem; 2016 Sep; 24(18):4347-4362. PubMed ID: 27485602
[TBL] [Abstract][Full Text] [Related]
49. Bronchospasmolytic activity and adenosine receptor binding of some newer 1,3-dipropyl-8-phenyl substituted xanthine derivatives.
Gumber D; Yadav D; Yadav R; Kachler S; Klotz KN
Chem Biol Drug Des; 2020 Jun; 95(6):600-609. PubMed ID: 32100461
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Petzer JP; Steyn S; Castagnoli KP; Chen JF; Schwarzschild MA; Van der Schyf CJ; Castagnoli N
Bioorg Med Chem; 2003 Apr; 11(7):1299-310. PubMed ID: 12628657
[TBL] [Abstract][Full Text] [Related]
51. Selective adenosine A2A receptor antagonists.
Ongini E; Monopoli A; Cacciari B; Baraldi PG
Farmaco; 2001; 56(1-2):87-90. PubMed ID: 11347973
[TBL] [Abstract][Full Text] [Related]
52. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.
Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Monopoli A; Ongini E; Varani K; Borea PA
J Med Chem; 2002 Jan; 45(1):115-26. PubMed ID: 11754583
[TBL] [Abstract][Full Text] [Related]
53. 2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives.
Areias F; Correia C; Rocha A; Teixeira S; Castro M; Brea J; Hu H; Carlsson J; Loza MI; Proença MF; Carvalho MA
Molecules; 2024 May; 29(11):. PubMed ID: 38893418
[TBL] [Abstract][Full Text] [Related]
54. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.
Yan L; Müller CE
J Med Chem; 2004 Feb; 47(4):1031-43. PubMed ID: 14761205
[TBL] [Abstract][Full Text] [Related]
55. 8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
Shimada J; Suzuki F; Nonaka H; Ishii A
J Med Chem; 1992 Mar; 35(5):924-30. PubMed ID: 1548682
[TBL] [Abstract][Full Text] [Related]
56. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
Müller CE; Shi D; Manning M; Daly JW
J Med Chem; 1993 Oct; 36(22):3341-9. PubMed ID: 8230124
[TBL] [Abstract][Full Text] [Related]
57. Molecular simulation of 8-styrylxanthines.
Mager PP; Reinhardt R; Richter M; Walther H; Rockel B
Drug Des Discov; 1995 Nov; 13(2):89-107. PubMed ID: 8872454
[TBL] [Abstract][Full Text] [Related]
58. Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine.
Nonaka Y; Shimada J; Nonaka H; Koike N; Aoki N; Kobayashi H; Kase H; Yamaguchi K; Suzuki F
J Med Chem; 1993 Nov; 36(23):3731-3. PubMed ID: 8246243
[No Abstract] [Full Text] [Related]
59. Synthesis and Evaluation of a New Series of 8-(2-Nitroaryl)Xanthines as Adenosine Receptor Ligands.
Bansal R; Kumar G; Rohilla S; Klotz KN; Kachler S; Young LC; Harvey AL
Drug Dev Res; 2016 Aug; 77(5):241-50. PubMed ID: 27404511
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.
Pfister JR; Belardinelli L; Lee G; Lum RT; Milner P; Stanley WC; Linden J; Baker SP; Schreiner G
J Med Chem; 1997 Jun; 40(12):1773-8. PubMed ID: 9191953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
